Literature DB >> 2530352

Synthesis and biological properties of N63-carboxamides of teicoplanin antibiotics. Structure-activity relationships.

A Malabarba1, A Trani, P Strazzolini, G Cietto, P Ferrari, G Tarzia, R Pallanza, M Berti.   

Abstract

The condensation of the carboxyl function of teicoplanin A2 (CTA) and its acidic hydrolysis pseudoaglycons (TB, TC) and aglycon (TD) with amines carrying various functional groups and chains produced amide derivatives with different isoelectric points and lipophilicities. Amide formation did not affect the ability of these compounds to bind to Ac2-L-Lys-D-Ala-D-Ala, a model for the natural peptide binding site in bacterial cell walls. The antimicrobial activities of teicoplanin amides were found to depend mostly on their ionic and lipophilic character and on the type and number of sugars present. Positively charged amides were generally more in vitro active than the respective unmodified antibiotics against Gram-positive organisms. In particular, most basic amides of CTA were markedly more active than teicoplanin against coagulase-negative staphylococci. A few amides of TC and most of those of TD also showed a certain activity against Gram-negative bacteria. In experimental Streptococcus pyogenes septicemia in the mouse, some basic amides were more active than the parent teicoplanins when administered subcutaneously. Some of those of CTA were also slightly more effective than teicoplanin by oral route.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530352     DOI: 10.1021/jm00131a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.

Authors:  M Berti; G Candiani; M Borgonovi; P Landini; F Ripamonti; R Scotti; L Cavenaghi; M Denaro; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Mathematical modeling of antimicrobial susceptibility data of Staphylococcus haemolyticus for 11 antimicrobial agents, including three experimental glycopeptides and an experimental lipoglycopeptide.

Authors:  P R Hunter; R C George; J W Griffiths
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

4.  The activity of glycopeptide antibiotics against resistant bacteria correlates with their ability to induce the resistance system.

Authors:  Min Jung Kwun; Hee-Jeon Hong
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

5.  N-Terminal guanidine derivatives of teicoplanin antibiotics strongly active against glycopeptide resistant Enterococcus faecium.

Authors:  Zsolt Szűcs; Ilona Bereczki; Erzsébet Rőth; Márton Milánkovits; Eszter Ostorházi; Gyula Batta; Lajos Nagy; Zsuzsanna Dombrádi; Anikó Borbás; Pál Herczegh
Journal:  J Antibiot (Tokyo)       Date:  2020-05-15       Impact factor: 2.649

6.  In vitro activity of the semisynthetic glycopeptide amide MDL 63,246.

Authors:  M T Kenny; M A Brackman; J K Dulworth
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

7.  Mechanism of uptake of deglucoteicoplanin amide derivatives across outer membranes of Escherichia coli and Pseudomonas aeruginosa.

Authors:  R E Hancock; S W Farmer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States.

Authors:  R N Jones; F W Goldstein; X Y Zhou
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

9.  In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.

Authors:  F Biavasco; E Manso; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

10.  Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Authors:  Jan Balzarini; Els Keyaerts; Leen Vijgen; Herman Egberink; Erik De Clercq; Marc Van Ranst; Svetlana S Printsevskaya; Eugenia N Olsufyeva; Svetlana E Solovieva; Maria N Preobrazhenskaya
Journal:  Antiviral Res       Date:  2006-04-06       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.